B1CTcu5: A frog-derived brevinin-1 peptide with anti-tuberculosis activity

Abraham, Parvin; Jose, Leny; Maliekal, Tessy Thomas; Kumar, Ram Mohan Ram; Kumar, K. Santhosh

doi:10.1016/j.peptides.2020.170373

Cited by 13 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has distinct defense mechanisms, in comparison with other bacteria, due to its capsule composition of peptidoglycans. It is also capable of remaining in the latency phase for many years with no symptoms of infection [ 56 ]. Thus, many studies against this bacterium have been carried out at the genetic-molecular and biochemical levels to reach new therapeutic objectives and control it, as conventional antibiotics are not effective enough, require a long time, and cause unpleasant adverse effects [ 57 ].…”

Section: Amp Applications In Critical-priority Bacteriamentioning

confidence: 99%

“…In a recent study, Abraham et al [ 56 ] synthesized a 21-residue peptide called B1CTcu5, which was originally isolated from the cutaneous secretion of Clinotarsus curtipes , a frog of Indian origin. The brevinin-1 family of AMP has shown promising results in the search for a new agent against tuberculosis.…”

Section: Amp Applications In Critical-priority Bacteriamentioning

confidence: 99%

“…Some AMPs present hemolytic activity, which is considered an important factor to be controlled and evaluated, as human cells could be lysed before the AMPs fulfill their objective [ 121 ]. However, some advances indicate that the manipulation of hydrophobicity could be crucial for this type of molecule, and for this reason, more studies of amino acid substitution within the peptide sequence must be carried out [ 56 ]. Furthermore, a previous study by our research group indicated that the use of microencapsulation with alginate by ionic gelation could decrease the hemolytic activity without affecting the antimicrobial activity of the Ctx(Ile 21 ) peptide, making it useful as an oral food additive in formulations against MDR bacteria [ 5 ].…”

Section: Challenges and Perspectivesmentioning

confidence: 99%

See 2 more Smart Citations

Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

et al. 2021

View full text Add to dashboard Cite

Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi-resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high-priority bacteria published in the WHO list.

show abstract

Section: Amp Applications In Critical-priority Bacteriamentioning

confidence: 99%

Section: Amp Applications In Critical-priority Bacteriamentioning

confidence: 99%

Section: Challenges and Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Brevinins are known for their antimicrobial activities against Gram-positive and Gram-negative bacteria. This cationic peptide was isolated from the skin secretion of the frog Clinotarsus curtipes [111,112].…”

Section: B1ctcu5mentioning

confidence: 99%

“…Moreover, at its MIC, the peptide was capable of completely inhibiting Mtb growing inside THP1-derived macrophages. Furthermore, it was deemed as non-toxic against this cell line, proving to be a potential anti-tubercular lead [112]. Nisin A and lacticin 3147 are two of the best characterized lantibiotics.…”

Section: B1ctcu5mentioning

confidence: 99%

Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review

et al. 2021

View full text Add to dashboard Cite

Despite being considered a public health emergency for the last 25 years, tuberculosis (TB) is still one of the deadliest infectious diseases, responsible for over a million deaths every year. The length and toxicity of available treatments and the increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis renders standard regimens increasingly inefficient and emphasizes the urgency to develop new approaches that are not only cost- and time-effective but also less toxic. Antimicrobial peptides (AMP) are small cationic and amphipathic molecules that play a vital role in the host immune system by acting as a first barrier against invading pathogens. The broad spectrum of properties that peptides possess make them one of the best possible alternatives for a new “post-antibiotic” era. In this context, research into AMP as potential anti-tubercular agents has been driven by the increasing danger revolving around the emergence of extremely-resistant strains, the innate resistance that mycobacteria possess and the low compliance of patients towards the toxic anti-TB treatments. In this review, we will focus on AMP from various sources, such as animal, non-animal and synthetic, with reported inhibitory activity towards Mycobacterium tuberculosis.

show abstract

Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review

Preethi

Anbarasu

2022

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

B1CTcu5: A frog-derived brevinin-1 peptide with anti-tuberculosis activity

Cited by 13 publications

References 23 publications

Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review

Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review

Contact Info

Product

Resources

About